Mesenchymal Stem Cell Therapy in Thailand

Almost everything sold as “stem cell therapy” is this. Mesenchymal stromal cell therapy uses connective-tissue-derived cells from fat, bone marrow or umbilical cord, and understanding what they are — and what they have and have not been shown to do — is the difference between an informed decision and an expensive one.

What MSCs are, and what they are not

Mesenchymal stromal cells are adult cells found in several tissues. They can be grown in culture, and under laboratory conditions they can be pushed toward bone, cartilage or fat lineages.

The name causes trouble. Many researchers prefer “stromal” over “stem” precisely because the evidence that these cells behave as true stem cells in the body — replacing lost tissue by becoming it — is much weaker than the marketing suggests.

They are not embryonic stem cells, and they are not the blood-forming cells used in transplant medicine — see HSCT versus MSC infusion.

Where they are taken from

Three sources dominate published work, and they are not equivalent.

• Adipose tissue — fat, collected by a small liposuction. Yields are high and collection is straightforward.
• Bone marrow — aspirated from the pelvis. The traditional source, with lower cell yield and a more uncomfortable harvest.
• Umbilical cord — donated after a normal birth, so allogeneic. Cells are younger, more uniform, and available without a harvest procedure.

A network meta-analysis compared cell types head to head in knee osteoarthritis — which cell and type are more beneficial — which is worth reading before accepting that the source does not matter.

How they are prepared in published trials

This describes the literature. Ask any clinic to describe its own process, because processes differ and the difference is not cosmetic.

Tissue is collected, cells isolated, then expanded in culture over roughly two to four weeks. Expansion matters because a raw harvest rarely contains a therapeutic number of cells.

Before use, cells are typically characterised against surface-marker criteria, checked for viability, and tested for bacterial and fungal contamination and for endotoxin. They are then used fresh or cryopreserved and thawed.

Dose, and why the numbers vary so much

Published doses span more than an order of magnitude, which makes cross-trial comparison difficult and makes “a stem cell treatment” an almost meaningless description of what you are buying.

Joint injections are typically expressed as a total cell count per joint; intravenous doses as cells per kilogram of body weight.

There is also the question of how many treatments. A randomised trial in knee osteoarthritis found repeated dosing outperformed a single dose — Repeated MSC Dosing Is Superior to a Single MSC Dose — and a dose-escalation trial has examined this directly in another indication — Randomized phase 2b dose-escalation trial of stem cell therapy. See MSC dosage research.

How they are given

Route is not a detail. It changes which evidence applies.

Intra-articular — into a joint. This is what nearly all the osteoarthritis evidence used.

Intravenous — into a vein, distributing systemically. Used for autoimmune, metabolic and inflammatory indications. Most infused cells are trapped in the lungs on first pass, which is one reason the mechanism is thought to be signalling rather than engraftment.

Intrathecal — into spinal fluid, used in neurological research. More invasive, and rarely appropriate outside a trial.

The proposed mechanism, labelled as proposed

Current thinking is that MSCs act mainly by secreting signalling molecules that modulate inflammation and influence resident cells, rather than by becoming new tissue themselves.

This is a shift from the original rationale, and it matters commercially: if the cells are messengers rather than building blocks, then claims about rebuilding joints are claims about the older, weaker model.

See MSC immunomodulation for what the mechanism research actually supports.

Where the human evidence is strongest

Knee osteoarthritis, by a clear margin — multiple randomised trials and a 2025 systematic review and meta-analysis — Efficacy and safety of mesenchymal stem cells in knee osteoarthritis.

There is randomised evidence in some narrower indications too: diabetic foot ulcers — A Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcer — and diabetic kidney disease — Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease.

A systematic review has assessed MSCs across autoimmune and rheumatic disease — mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases.

Where it is weakest

Neurological conditions, organ regeneration, ageing and general wellness. Studied in places, established nowhere.

A systematic review of MSCs in traumatic spinal cord injury exists — Mesenchymal Stem Cell Therapy in Traumatic Spinal Cord Injury: A Systematic Review — and a review existing is not the same as a treatment working.

Anything sold for “anti-ageing” or general wellness has no reliable human evidence, whatever the accompanying imagery suggests.

Risks

Short-term tolerability across trials has generally been reported as good, with transient injection-site pain, swelling or brief fever being the common events.

Procedure risks are real and separate: joint infection after an injection, donor-site complications after a harvest, and the ordinary risks of intravenous access.

Long-term data is thin because the treatments are not old, and contamination and preparation failures are documented in the unregulated sector — see adverse events.

Questions worth asking before paying

The answers separate a clinic describing its own evidence from one borrowing someone else’s.

• Which source — adipose, marrow or cord — and autologous or allogeneic?
• How many cells, and what is that number based on?
• Expanded in culture, and for how long?
• What release testing is done before the cells are given?
• Which published trial used this cell type, at this dose, by this route, in my condition?

See autologous therapy and cord-derived therapy for how those choices differ.

Frequently asked questions

Requesting a medical evaluation

Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.

Message us on WhatsApp

This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.